Exclusive license for the commercialization of GLP-1 products in China

Exclusive license to develop and commercialize programmed therapeutic cells in Greater China

Exclusive license for the distribution and promotion of insulin products

Collaboration for clinical development and commercialization of MCM1 in China

Exclusive partnership to commercialize liposomal products utilizing NanoX™ in Mainland China

Priority for potential licensing or development of two ophthalmic-related disease products

Exclusive right to develop and commercialize Remitch in China

Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology

Collaboration for clinical development and commercialization of multiple biosimilars in China

Potential licensing priorities for four inner ear disease related research products

Investment to research and develop early stage cancer drugs